Complement factor d antagonist antibodies and conjugates thereof
AssigneeKodiak Sciences Inc.
InventorsDaniel Victor Perlroth, Wah Yuen To, Hong Liang, Rachel Marie DeVay Jacobson, Fernando Corrêa
Life of this patent
Estimating the term…
Abstract
The present invention provides antagonizing antibodies that bind to complement factor D (CFD), conjugates thereof, and methods of using same. The anti-CFD antibodies can be used therapeutically alone or in combination with other therapeutics to treat age related macular degeneration and other diseases.
Claims34
-12. (canceled)
A conjugate comprising:
- an isolated antagonistic antibody that binds to CFD, the antibody comprising:
- a CDRH1 that is the CDRH1 in SEQ ID NO:
- 520;
- a CDRH2 that is the CDRH2 in SEQ ID NO:
- 520;
- a CDRH3 that is the CDRH3 in SEQ ID NO:
- 520;
- a CDRL1 that is the CDRL1 in SEQ ID NO:
- 525;
- a CDRL2 that is the CDRL2 in SEQ ID NO:
- 525;
- a CDRL3 that is the CDRL3 in SEQ ID NO:
- 525;
- at least one of the following mutations (EU numbering):
- L234A, L235A, and G237A;
- and
- at least one of the following mutations (EU numbering):
- Q347C or L443C;
- and
- a polymer, wherein the polymer is covalently attached to the antibody.
-19. (canceled)
The conjugate of claim 36, wherein the heavy chain variable region of the antibody comprises three complementarity determining regions (CDRs) comprising the amino acid sequences shown in SEQ ID NO:
- 520.
The conjugate of claim 36, wherein the light chain variable region of the antibody comprises three complementarity determining regions (CDRs) comprising the amino acid sequences shown in SEQ ID NO:
- 525.
The conjugate of claim 36, wherein the heavy chain variable region (VH) of the antibody comprises three CDRs comprising the amino acid sequences shown in SEQ ID NO:
- 541, SEQ ID NO:
- 542, and SEQ ID NO:
- 543, and the light chain variable region (VL) of the antibody comprises three CDRs comprising the amino acid sequences shown in SEQ ID NO:
- 544, SEQ ID NO:
- 545, and SEQ ID NO:
- 546.
The conjugate of claim 36, wherein the antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO:
- 183, with or without the C-terminal lysine, and a light chain comprising the amino acid sequence shown in SEQ ID NO:
- 184.
-35. (canceled)
A conjugate comprising:
- (a) an isolated antagonist antibody that specifically binds to complement factor D (CFD);
- and
- (b) a phosphorylcholine containing polymer, wherein the polymer is covalently bonded to the antibody.
A conjugate comprising:
- (a) an isolated antagonist antibody that specifically binds to complement factor D (CFD);
- and
- (b) a polymer comprising a zwitterionic monomer, wherein the zwitterionic monomer is selected from the group consisting of HEMA-phosphorylcholine, PEG, biocompatible fatty acids and derivatives thereof, Hydroxy Alkyl Starch (HAS), Hydroxy Ethyl Starch (HES), Poly Ethylene Glycol (PEG), Poly (Glyx-Sery) (HAP), Hyaluronic acid (HA), Heparosan polymers (HEP), Fleximers, Dextran, Poly-sialic acids (PSA), Fc domains, Transferrin, Albumin, Elastin like (ELP) peptides, XTEN polymers, PAS polymers, PA polymers, Albumin binding peptides, CTP peptides, and FcRn binding peptides.
(canceled)
(canceled)
-48. (canceled)
(canceled)
(canceled)
(canceled)
-73. (canceled)
-80. (canceled)
Dependencies are inferred from the claim text.